title: Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial.
abstract: Patients with ALS may have insufficientenergy substrates, due to dysphagia and hypermetabolism, which adversely affects the prognosis. Hyperlipidaemia has been reported to be associated with ALS and to represent a significant prognostic factor for survival in ALS. The aim of this study was to examine the prevalence of dyslipidaemia among a cohort of patients with ALS and how the lipid profile of patients with ALS influenced the prognosis. This was a prospective observational cohort study comprising 512 ALS patients, recruited for the TRO19622 (Olesoxime) investigational medicinal product trial. Fasting serum concentrations of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were measured as part of routine monitoring in the trial. Seventy-three percent of the participants had hypercholesterolaemia (defined as total cholesterol ≥ 5.1 mmol/l) at the screening visit. The prevalence of hypercholesterolaemia decreased with time and was 64% at 18 months follow-up. On unadjusted analysis total cholesterol, LDL-C and LDL/HDL ratio had a statistically significant effect on survival (p = 0.015, 0.003 and 0.027, respectively). When adjusted for prognostic covariates, however, none of the lipid measures was found to have a statistically significant effect on survival. In conclusion, prognosis in ALS is not influenced by the lipid profile of patients.
authors.affiliation: a The Academic Neurology Unit, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield , Sheffield , UK.
authors.forename: Muhammad K
authors.initials: MK
authors.lastname: Rafiq
authors.affiliation: b The Clinical Trials Research Unit, School of Health and Related Research (ScHARR), University of Sheffield , Sheffield , UK.
authors.forename: Ellen
authors.initials: E
authors.lastname: Lee
authors.affiliation: b The Clinical Trials Research Unit, School of Health and Related Research (ScHARR), University of Sheffield , Sheffield , UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Bradburn
authors.affiliation: a The Academic Neurology Unit, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield , Sheffield , UK.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: McDermott
authors.affiliation: a The Academic Neurology Unit, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield , Sheffield , UK.
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Shaw
mesh_terms: D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D002783:Cholestenones / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D015331:Cohort Studies; D050171:Dyslipidemias / Q000097:blood / Q000453:epidemiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies
chemical_list: D002783:Cholestenones; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D002784:Cholesterol; C522838:olesoxime
keywords: Amyotrophic lateral sclerosis; lipid profile; metabolism; prognosis; survival